Search and analyze individual stocks with comprehensive metrics
Themis Medicare Ltd
Fundamental Score
Themis Medicare Ltd Share Price Live NSE/BSE
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of THEMISMED across key market metrics for learning purposes.
Positive Indicators
5 factors identified
Strong Operating Margins (17.72%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages. This indicates sustainable profitability potential.
Consistent Growth Track Record (15.00% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model and market opportunity execution over time.
Conservative Debt Levels (D/E: 0.25)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns and flexibility for growth investments.
Strong Cash Generation (₹66.09 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (67.15%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment while ensuring adequate liquidity.
Risk Factors
7 factors identified
Below-Average Return on Equity (7.65%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Profit Decline Concern (-125.33%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes. Monitor for recovery signs and management guidance.
Revenue Contraction (-33.35%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions and competitive positioning. Monitor recovery strategies.
Weak Earnings Growth (3.88% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation. Consider growth catalysts and competitive positioning.
Stagnant Profit Growth (3.91% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity. Assess transformation initiatives.
Weak Interest Coverage (-1.58x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability. Monitor cash flow and debt reduction plans.
Limited Institutional Interest (FII+DII: 0.07%)
Observation: Low institutional participation may affect liquidity and visibility.
Analysis: Limited institutional interest may indicate size constraints or visibility issues in the investment community.
Loading Peer Comparison
Finding companies in the Pharmaceuticals sector...
Financial Statements
Comprehensive financial data for Themis Medicare Ltd
About THEMISMED
Business Overview
Themis Medicare Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India and internationally. It offers active pharmaceutical ingredients (APIs) and formulations used in various therapeutic areas, including anti-tuberculosis, analgesic and anti-inflammatory, analgesic and antispasmodic, analgesics, anesthesia, antacid-antiflatulent, anti-fungal, antibiotic, anti-diabetic, anti-emetic, anti-hypertensive, anti-allergic and anti-inflammatory, anti-allergic and appetite stimulant, anticoagulant, antifibrolytic, antimalarial, anti-muscarinic, antioxidant, calcium, cardiovascular, corticosteroid, electrolytes, expectorant, hematinic, hemostatic agent, hemostatic agent with anesthetic, hormones, immunomodulator with anti-viral, muscle relaxant, narcotic analgesic, neuropathy, nutraceuticals, PPI, probiotic, reversal for muscle relaxant, sedatives, skeletal muscle relaxant, skeletal muscle relaxant and analgesic and anti-inflammatory, vasodilator, vasopressors, and vitamins. The company was formerly known as Themis Chemicals and changed its name to Themis Medicare Limited in 2001. Themis Medicare Limited was founded in 1952 and is based in Mumbai, India.
Company Details
Key Leadership
Corporate Events
THEMISMED Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of Themis Medicare Ltd (THEMISMED)?
As of 14 Jan 2026, 11:00 am IST, Themis Medicare Ltd (THEMISMED) is currently trading at ₹95.65. The stock has a market capitalization of ₹969.87 (Cr).
Is THEMISMED share price Overvalued or Undervalued?
THEMISMED is currently trading at a P/E ratio of 0.00x, compared to the industry average of 31.77x. Based on this relative valuation, the stock appears to be Fairly Valued against its sector peers.
What factors affect the Themis Medicare Ltd share price?
Key factors influencing THEMISMED's price include its quarterly earnings growth (Sales Growth: -33.35%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Themis Medicare Ltd a good stock for long-term investment?
Themis Medicare Ltd shows a 5-year Profit Growth of 3.91% and an ROE of 7.65%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.25 before investing.
How does Themis Medicare Ltd compare with its industry peers?
Themis Medicare Ltd competes with major peers in the Pharmaceuticals. Investors should compare THEMISMED's P/E of 0.00x and ROE of 7.65% against the industry averages to determine its competitive standing.
What is the P/E ratio of THEMISMED and what does it mean?
THEMISMED has a P/E ratio of N/Ax compared to the industry average of 31.77x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹N/A for every ₹1 of annual earnings.
How is THEMISMED performing according to Bull Run's analysis?
THEMISMED has a Bull Run fundamental score of 30/100, which indicates concerns that require careful analysis. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.
What sector and industry does THEMISMED belong to?
THEMISMED operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Themis Medicare Ltd.
What is Return on Equity (ROE) and why is it important for THEMISMED?
THEMISMED has an ROE of 7.65%, which suggests challenges in generating returns from shareholders' equity. Return on Equity measures how efficiently Themis Medicare Ltd generates profits from shareholders' equity.
How is THEMISMED's debt-to-equity ratio and what does it indicate?
THEMISMED has a debt-to-equity ratio of 0.25, which indicates conservative financing with low financial risk. A ratio below 1.0 generally indicates conservative financing.
What is THEMISMED's dividend yield and is it a good dividend stock?
THEMISMED offers a dividend yield of 0.48%, which means you receive ₹0.48 annual dividend for every ₹100 invested.
How has THEMISMED grown over the past 5 years?
THEMISMED has achieved 5-year growth rates of: Sales Growth 15.00%, Profit Growth 3.91%, and EPS Growth 3.88%.
What is the promoter holding in THEMISMED and why does it matter?
Promoters hold 67.15% of THEMISMED shares, with 2.43% of promoter shares pledged. High promoter holding often indicates strong management confidence.
What is THEMISMED's market capitalization category?
THEMISMED has a market capitalization of ₹970 crores, placing it in the Small-cap category.
How volatile is THEMISMED stock?
THEMISMED has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is the 52-week high and low for THEMISMED?
THEMISMED has a 52-week high of ₹N/A and low of ₹N/A.
What is THEMISMED's operating profit margin trend?
THEMISMED has a 5-year average Operating Profit Margin (OPM) of 17.72%, indicating the company's operational efficiency.
How is THEMISMED's quarterly performance?
Recent quarterly performance shows YoY Sales Growth of -33.35% and YoY Profit Growth of -125.33%.
What is the institutional holding pattern in THEMISMED?
THEMISMED has FII holding of 0.06% and DII holding of 0.01%. Significant institutional holding often suggests professional confidence in the stock.